Demonstrates effective sulfadiazine removal in contaminated soil, suggesting improved ecological safety in cold regions.
The bioremediation of antibiotic-contaminated soil in cold regions is hindered by low degradation efficiency and insufficient ecological safety evaluation. This study developed a solid-state fermentation agent using the psychrotolerant white-rot fungus Bjerkandera adusta DH0817 cultured on rice straw and bran, and evaluated its efficacy in sulfadiazine (SDZ)-contaminated soil at 10°C. An application of the agent at 5% (w/w) achieved 73.9% SDZ removal within 30 days. Integrating high-throughput sequencing, functional prediction, and RT-qPCR analyses, this study showed that the introduction of DH0817 significantly accelerated the degradation of SDZ. Furthermore, it was associated with a reduction in both the abundance and diversity of soil bacteria and fungi. Notable alterations in community structure were observed, characterized by decreased abundances of SDZ-tolerant genera such as Pseudaminobacter and TM7a , alongside significant increases in genera including Acinetobacter , Paenarthrobacter , and Penicillium . The predictive results indicated that the application of strain DH0817 could yield beneficial effects on the soil microbial function. Additionally, the introduction of this strain resulted in a decrease in the copy numbers of sulfonamide resistance genes (SA-ARGs), Multidrug resistance genes (MD-ARGs), and Mobile genetic elements (MGEs), while concurrently increasing Aminoglycoside resistance genes (AM-ARGs) and Macrolide-lincosamide-streptogramin B resistance genes (MLSB-ARGs). This phenomenon may potentially heighten public health. This study provides an effective microbial agent for the bioremediation of antibiotic-contaminated soils in cold regions, emphasizing the necessity of assessing soil microbial communities and ARGs throughout the remediation process. Furthermore, it establishes a theoretical foundation for the ecological risk evaluation of environmental microbial remediation technologies.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: